Verve Therapeutics to Participate in Upcoming Investor Conferences
Verve Therapeutics (VERV), a clinical-stage company focused on genetic medicines for cardiovascular disease, has announced its participation in two major investor conferences in June 2025. The company's management will engage in fireside chats at the Jefferies Global Healthcare Conference on June 4 at 9:20 a.m. ET in New York, and the Goldman Sachs 46th Annual Global Healthcare Conference on June 9 at 11:20 a.m. ET in Miami. Both events will be available via webcast on the company's website and archived for 30 days.
Verve Therapeutics (VERV), un'azienda in fase clinica specializzata in terapie genetiche per le malattie cardiovascolari, ha annunciato la sua partecipazione a due importanti conferenze per investitori nel giugno 2025. Il management dell'azienda parteciperà a discussioni informali al Jefferies Global Healthcare Conference il 4 giugno alle 9:20 ET a New York, e al Goldman Sachs 46th Annual Global Healthcare Conference il 9 giugno alle 11:20 ET a Miami. Entrambi gli eventi saranno trasmessi in webcast sul sito web dell'azienda e resteranno disponibili in archivio per 30 giorni.
Verve Therapeutics (VERV), una empresa en etapa clínica centrada en medicamentos genéticos para enfermedades cardiovasculares, ha anunciado su participación en dos importantes conferencias para inversores en junio de 2025. La dirección de la empresa participará en charlas informales en la Jefferies Global Healthcare Conference el 4 de junio a las 9:20 a.m. ET en Nueva York, y en la Goldman Sachs 46th Annual Global Healthcare Conference el 9 de junio a las 11:20 a.m. ET en Miami. Ambos eventos estarán disponibles vía webcast en el sitio web de la empresa y se archivarán durante 30 días.
Verve Therapeutics (VERV)는 심혈관 질환을 위한 유전자 치료제에 중점을 둔 임상 단계 기업으로, 2025년 6월 두 개의 주요 투자자 컨퍼런스에 참여할 예정임을 발표했습니다. 회사 경영진은 6월 4일 오전 9시 20분(동부시간) 뉴욕에서 열리는 Jefferies Global Healthcare Conference와 6월 9일 오전 11시 20분(동부시간) 마이애미에서 열리는 Goldman Sachs 46th Annual Global Healthcare Conference에서 대화에 참여할 예정입니다. 두 행사 모두 회사 웹사이트를 통해 웹캐스트로 제공되며 30일간 아카이브됩니다.
Verve Therapeutics (VERV), une entreprise en phase clinique spécialisée dans les médicaments génétiques pour les maladies cardiovasculaires, a annoncé sa participation à deux grandes conférences pour investisseurs en juin 2025. La direction de l'entreprise participera à des discussions informelles lors de la Jefferies Global Healthcare Conference le 4 juin à 9h20 ET à New York, ainsi qu'à la Goldman Sachs 46th Annual Global Healthcare Conference le 9 juin à 11h20 ET à Miami. Les deux événements seront diffusés en webcast sur le site internet de l'entreprise et archivés pendant 30 jours.
Verve Therapeutics (VERV), ein klinisch fortgeschrittenes Unternehmen, das sich auf genetische Therapien für Herz-Kreislauf-Erkrankungen spezialisiert hat, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im Juni 2025 angekündigt. Das Management des Unternehmens wird am Jefferies Global Healthcare Conference am 4. Juni um 9:20 Uhr ET in New York und am Goldman Sachs 46th Annual Global Healthcare Conference am 9. Juni um 11:20 Uhr ET in Miami in informellen Gesprächen teilnehmen. Beide Veranstaltungen werden per Webcast auf der Unternehmenswebsite verfügbar sein und für 30 Tage archiviert.
- None.
- None.
BOSTON , May 28, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that management will participate in fireside chats during the following investor conferences:
- Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 9:20 a.m. ET in New York, NY
- Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025, at 11:20 a.m. ET in Miami, FL
Live webcasts will be available in the investor section of the company's website at www.vervetx.com. The webcasts will be archived for 30 days following the fireside chats.
About Verve Therapeutics
Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The company’s lead programs –VERVE-102, VERVE-201, and VERVE-301 – target the three cholesterol drivers of atherosclerosis: low-density lipoprotein cholesterol (LDL-C), triglycerides (TRLs), and lipoprotein (a) [Lp(a)]. VERVE-102 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established atherosclerotic cardiovascular disease (ASCVD) who continue to be impacted by high LDL-C levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia, where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies, and homozygous familial hypercholesterolemia (HoFH). VERVE-301 is designed to permanently turn off the LPA gene to reduce Lp(a) levels. Lp(a) is a genetically validated, independent risk factor for ASCVD, ischemic stroke, thrombosis, and aortic stenosis. For more information, please visit www.VerveTx.com.
Investor Contact
Jen Robinson
Verve Therapeutics, Inc.
jrobinson@vervetx.com
Media Contact
Ashlea Kosikowski
1AB
ashlea@1abmedia.com
FAQ
When is Verve Therapeutics (VERV) presenting at the Jefferies Global Healthcare Conference 2025?
Where can I watch Verve Therapeutics' (VERV) investor conference presentations?
What conferences is Verve Therapeutics (VERV) attending in June 2025?
What time is Verve Therapeutics' (VERV) presentation at the Goldman Sachs Healthcare Conference?
